The introduction of targeted cancer drugs fulfilled the promise of personalized (precision) medicine, offering great benefit to some patients, great expense to others. Martell was organized to launch the next paradigm—how best to manage precision treatments. This can be accomplished with inexpensive blood tests that quickly document drug efficacy, remission and recurrence. We consider our mission de-escalation: less medication, less cost, a better quality of life.

It’s been 22 years now, yet every morning I wake up, feel the tingling and wonder, maybe just for a few seconds.





Metastatic breast cancer is now considered a chronic condition with effective treatments that in many ways allow women to lead a normal or near normal life. Yet, many women live with the fear that their cancer may no longer be responding to medication or the disease has flared in advance of overt clinical symptoms. We believe that a simple blood test can effectively monitor medication and help detect recurrences of HER2 tumors. Plus, monitoring helps to reduce anxiety. Therein lies the value of HERTEST for women with metastatic HER2 tumors—the possibility of real-time, actionable information and additional peace of mind.


The PD-1/PD-L1 axis is an important mechanism often regulating tumor growth. Recognition has led to the introduction of  new drugs called checkpoint inhibitors. Sometimes spectacular, always expensive, treatment could be better managed with a monitoring blood test. Martell is introducing CHECKMARK with the hope it will fulfill that need.

About Martell Diagnostic

Martell Diagnostic Laboratories

 

Founded: 2008

Business model: reference laboratory


Ownership: venture-backed

Location: Roseville, MN



Selected News

Launching CHECKMARK
(October 2018)
Available as Laboratory Developed Test (LDT) to hospitals and clinics. 


New Source of Immunoassay Reagents
(June 2018)
Martell forms relationship with Massachusetts vendor to develop
and manufacture recombinant rabbit monoclonal antibodies

Executive Appointments
(December 2017)
The board of directors is pleased to announced Dr. Steven P. Stoesz as President and Chief Operating Officer, and Frank R. McEvoy as Chief Financial Officer. Anthony Wlazlow, Ph.D., has also joined Martell as head of Product Development.


Martell signs Laboratory Service Agreement with Moffitt Cancer Center 

(October 2017)
The Company will support a Phase II clinical trial of a new anti-HER2 drug combination.


Welcome Jessica McDougall
(July 2016)
Jessica will be running our ELISA tests under the supervision of our Laboratory Manager and pathologist Laboratory Director.


New Evidence Supports Serum HER2 Monitoring

(March 2016)
See a recent article published in the Journal of Clinical Oncology (Lee CK, et al, March 2016.)